Post-Operative Nausea And Vomiting Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Post-Operative Nausea And Vomiting Market Expected To Become By 2029 Compared With Its 2025 Level?

Recent years have witnessed robust expansion in the post-operative nausea and vomiting market size. This market is anticipated to expand from $2.11 billion in 2024 to $2.25 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical growth experienced by the market can be ascribed to several factors, including heightened research and development activities, an escalating demand for sophisticated therapies, an increase in healthcare expenditure, a stronger emphasis on personalized medicine, and the expanding integration of digital health technologies.

The post-operative nausea and vomiting market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.94 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. Several factors contribute to this growth during the projection period, including an increasing need for pharmaceuticals, the proliferation of combination therapy, heightened awareness coupled with greater healthcare investments, an expanding elderly demographic, and a growing incidence of cancer. Key developments expected within the forecast timeframe encompass advanced antiemetic treatments, collaborative strategies, novel drug formulations, the incorporation of sophisticated diagnostic instruments, and electronic simulation technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

Which Factors And Drivers Are Influencing The Post-Operative Nausea And Vomiting Market In 2025?

The increasing volume of surgical operations is anticipated to drive expansion in the post-operative nausea and vomiting market in the future. These procedures involve medical interventions employing instruments to identify, address, or extract compromised tissues, organs, or anomalies through incision or manipulation. The escalation in surgical volumes stems from progress in medical technology, making operations safer, more efficacious, and less invasive, thus boosting patient willingness and broader utilization. Effective management of post-operative nausea and vomiting improves surgical processes by elevating patient comfort, shortening recovery periods, lowering complication risks, facilitating seamless post-operative care, and ultimately bettering overall surgical results. For example, data from November 2024, released by the Australian Institute of Health and Welfare, an Australian government body, indicated that during the 2023–24 timeframe, 771,600 patients underwent surgery from public hospital elective waiting lists. This figure represents a 4.9% rise when contrasted with 2022–23. Consequently, the growing frequency of surgical interventions is a key factor propelling the expansion of the post-operative nausea and vomiting market.

How Is The Post-Operative Nausea And Vomiting Market Segmented?

The post-operative nausea and vomitingmarket covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists; Steroids; Dopamine Antagonists; Neurokinin NK-1 Receptor Antagonists; Non-pharmacological Treatment; Other Treatment Types

2) By Route Of Administration: Oral; Intravenous; Transdermal; Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery; Gynecological Surgery; General Surgery; Cardiac Surgery; Ophthalmic Surgery

5) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron; Granisetron; Palonosetron; Dolasetron; Tropisetron

2) By Steroids Type: Dexamethasone; Methylprednisolone; Hydrocortisone; Prednisolone; Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide; Droperidol; Prochlorperazine; Domperidone; Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant; Fosaprepitant; Rolapitant; Netupitant; Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure; Aromatherapy; Hypnotherapy; Electroacupuncture; Ginger Supplements

6) By Other Treatment Types: Antihistamines; Anticholinergics; Cannabinoids; Combination Therapy; Herbal & Natural Remedies

What Trends Are Expected To Drive The Post-Operative Nausea And Vomiting Market?

Leading companies in the post-operative nausea and vomiting market are concentrating on developing crucial injectable medications that use advanced emulsion formulations and sustained-release technology. This effort aims to improve efficacy and deliver extended symptom relief for surgical patients. Critical injectable medications are defined as essential drugs administered via injection, designed to offer immediate and effective treatment for serious or urgent medical conditions. For instance, in July 2024, Avenacy, a US-based specialty pharmaceutical company, launched Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials, intended to help healthcare providers reduce dosing errors and enhance patient safety. This injection is indicated for preventing nausea and vomiting caused by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours following surgery, providing a reliable treatment option for patients at risk of these conditions.

Which Key Players Are Driving Competition In The Post-Operative Nausea And Vomiting Market?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited. , Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc. , Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Post-Operative Nausea And Vomiting Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2025, By The Business Research Company

Antiemetics And Antinauseants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiemetics-and-antinauseants-global-market-report

Chemotherapy Induced Nausea And Vomiting Cinv Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Chemotherapy Induced Nausea And Vomiting Cinv Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795